Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 84,894 Shares of Company Stock

Posted by Jeff Wilder on Oct 30th, 2026

Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $31.39, for a total transaction of $2,664,822.66. Following the completion of the sale, the insider owned 165,953 shares of the company’s stock, valued at $5,209,264.67. This represents a 33.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total transaction of $3,304,428.49.
On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.52, for a total transaction of $4,044,632.48.
On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total transaction of $4,525,301.06.
On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total transaction of $3,924,676.63.
On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total transaction of $6,329,182.65.
On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total transaction of $3,960,491.56.
On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total transaction of $1,988,880.72.
On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total transaction of $3,674.72.
On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.73, for a total transaction of $4,812,181.01.

Alamar Biosciences Price Performance

ALMR stock opened at $34.04 on Friday. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03. The stock’s 50-day moving average is $30.73. Alamar Biosciences, Inc. has a 1 year low of $18.84 and a 1 year high of $39.61.

Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. The firm had revenue of $29.43 million during the quarter. As a group, equities analysts predict that Alamar Biosciences, Inc. will post -1.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ALMR. Braidwell LP acquired a new position in shares of Alamar Biosciences during the second quarter valued at about $29,365,000. Wellington Management Group LLP acquired a new stake in shares of Alamar Biosciences in the 2nd quarter worth about $12,407,000. State Street Corp acquired a new stake in shares of Alamar Biosciences in the 2nd quarter worth about $3,930,000. Sumitomo Mitsui Trust Group Inc. lifted its position in Alamar Biosciences by 18.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after acquiring an additional 10,461 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in Alamar Biosciences in the 2nd quarter valued at about $283,000.

Analyst Ratings Changes

A number of equities research analysts have commented on ALMR shares. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Stifel Nicolaus boosted their price objective on Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings lowered Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Finally, JPMorgan Chase & Co. increased their target price on Alamar Biosciences from $32.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Alamar Biosciences has an average rating of “Hold” and a consensus target price of $31.80.

Get Our Latest Analysis on ALMR

Alamar Biosciences News Roundup

Here are the key news stories impacting Alamar Biosciences this week:

Positive Sentiment: Strong ALS study validates Alamar’s technology. Emory researchers reported that a 10-protein blood signature detected ALS with 98.3% accuracy and outperformed a leading individual biomarker, including in difficult-to-diagnose cases. Publication in Nature Communications could improve the visibility and commercial credibility of Alamar’s NULISA proteomics platform. Alamar Biosciences’ Protein Signature Detects ALS With 98.3% Accuracy in Study
Neutral Sentiment: Analyst views remain mixed. Earlier upgrades from Stifel and JPMorgan set price targets of $32 and $35, respectively, while Weiss Ratings downgraded the stock to sell. The broader analyst consensus is “Hold,” with an average target of $31.80, below the company’s recent trading range. Alamar remains unprofitable, although its latest quarterly loss was narrower than expected and revenue totaled $29.43 million.
Negative Sentiment: Major shareholder Qiming continued a substantial selling program. Corporate GP VI Ltd. Qiming sold 100,837 shares on October 28 and 84,894 shares on October 27, following additional sales on October 26 and earlier dates. Across the reported transactions from October 15 through October 28, the shareholder sold approximately 1.2 million shares, reducing its position to 164,191 shares. The repeated insider-related selling may weigh on sentiment and suggests a significant near-term supply overhang. Alamar Biosciences SEC Insider Sale Filing

About Alamar Biosciences

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.